Radiation Oncology Institute launched with $5 million ASTRO grant
September 1st 2008FAIRFAX, Virginia-The American Society for Therapeutic Radiology and Oncology (ASTRO) has invested $5 million in the newly created Radiation Oncology Institute (ROI). The goal of ROI is to support research and education in radiation therapy.
Dual-energy CT scanning captures subtle pancreatic masses
September 1st 2008LAS VEGAS-The increased speed and improved visualization of dual-energy CT helps pinpoint lesions at an earlier, more treatable stage. Faster and better visualization are the main reasons to use dual-energy CT for the assessment of pancreatic masses, according to a radiologist from the University of Munich.
Intrabone route may delay engraftment failure
September 1st 2008GENOA-Investigators from the San Martino Hospital in Italy are reporting that direct intrabone cord-blood transplantation overcomes graft failure even when low numbers of human leucocyte antigen-mismatched cord-blood cells are transplanted.
‘Oxaliplatin should be a part of standard therapy’
September 1st 2008Taken together, the results of the C-07 and MOSAIC trials suggest that oxaliplatin improves both disease-free and overall survival in this population [resected stage II-III colon cancer patients], said Dr. Goldberg, of the University of North Carolina Lineberger Comprehensive Cancer Center.
FDA Approves Oral Palonosetron for Prevention of Acute Chemotherapy-Induced Nausea and Vomiting
September 1st 2008The US Food and Drug Administration (FDA) has approved a new oral formulation of palonosetron hydrochloride (Aloxi) for the prevention of chemotherapy-induced nausea and vomiting (CINV). Oral administration of palonosetron capsules is indicated for the prevention of acute nausea and vomiting following initial and repeat courses of moderately emetogenic chemotherapy. A single 0.5-mg palonosetron capsule is administered approximately 1 hour prior to the start of chemotherapy.
The surgeon who challenged the breast ca paradigm
September 1st 2008Bernard Fisher, MD received his medical degree in 1943 from the University of Pittsburgh School of Medicine. As a young doctor, he was torn between a life in the operating room and one in the research lab. His curiosity about the biology of the diseases that were being treated by surgery eventually led to his decision to combine those interests.
Growth hormone deficiency spurs late effects of childhood cancer
September 1st 2008NIAGARA-ON-THE-LAKE, Canada-Long-term survivors of childhood cancer are at increased risk of several late effects, including premature cardiovascular disease and insulin resistance as young adults. New research suggests that one cause of these conditions may be growth hormone deficiency (GHD) caused by cancer therapy.
Are rebates for ca drugs a good deal?
September 1st 2008Basically, the manufacturer list price for darbepoetin is so high that it is nearly impossible to buy it as a single-source drug. Instead, companies are creatively bundling drugs, putting physicians under contractual obligation to purchase drugs as a package in order to get the best price and get the “rebate.”
Women reveal only mild anxiety after double mastectomy
September 1st 2008Deciding on a bilateral mastectomy is a bold move for any woman. But for a Hollywood actress, whose very livelihood depends in large part on her being attractive, such a drastic step could verge on foolhardy. It was both heartening and surprising when 36-year-old actress Christina Applegate, star of the ABC TV show Samantha Who?, announced that she had undergone a double mastectomy.
High cost of biologics takes a toll on hem/onc practices
August 2nd 2008The difficulty of manufacturing new chemotherapeutic agents-particularly specially formulated biologic cytotoxins-escalates the financial outlay that must be made by physicians as well as driving up the cost of drug delivery to patients, said Howard A. Burris III, MD, chief medical officer and director of drug development at the Sarah Cannon Research Institute and associate with Tennessee Oncology, both in Nashville.
FDA mandates changes to ESA labeling info
August 1st 2008New labeling for Aranesp and Procrit will tighten the use of both medications in cancer patients. The Food and Drug Administration ordered Amgen of Thousand Oaks, California to make changes to the prescribing information for its anemia drug darbepoetin alfa (Aranesp). Johnson & Johnson’s Ortho Biotech had already accepted the changes for the labeling of its ESA epoetin alfa (Procrit).
Avastin/sunitnib RCC trial closes after serious toxicities
August 1st 2008The lead investigator in an evaluation of bevacizumab (Avastin) combined with sunitinib malate (Sutent) for renal cell carcinoma (RCC) said the project would be abandoned. FDA issued a product safety alert after Genentech, Avastin’s developer, reported serious complications in several patients enrolled in the phase I trial.